Sub-nanomolar affinity · low intrinsic activity
IUPAC: (2S)-2-[(5R,6R,7R,14S)-17-(cyclopropylmethyl)-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-ethanomorphinan-7α-yl]-3,3-dimethylbutan-2-ol · C29H41NO4 · MW 467.65 g/mol · CAS 52485-79-7
Buprenorphine. A semisynthetic orvinol — thebaine-derived, of the 6,14-endo-ethano-oripavine family, cousin to etorphine and to BU72. Where fentanyl is a picomolar-efficient full agonist that drives the receptor as hard as it will go, buprenorphine binds harder and lets go slower yet refuses to push the receptor all the way — a high-affinity, slow-dissociating partial µ-agonist and functional κ-antagonist. Trade: Subutex, Suboxone (with naloxone), Sublocade, Butrans, Temgesic, Belbuca.
Buprenorphine occupies the same orthosteric pocket of the µ-opioid receptor (MOR) as morphine, fentanyl and the endogenous enkephalins, but two properties make it pharmacologically unlike any of them. First, its affinity is sub-nanomolar — human cloned-receptor displacement assays put Ki between ~0.09 and 1.5 nM, roughly an order of magnitude tighter than fentanyl. Second, its intrinsic efficacy is low: once bound, it recruits Gi/o and inhibits adenylyl cyclase only partially, producing a submaximal ceiling of receptor activation no matter how much drug is present.
Binds MOR at Ki ~0.2 nM but caps Gi/o coupling well below the Emax of a full agonist. Analgesia and euphoria plateau; critically, so does brainstem respiratory depression — the pharmacological basis of the ceiling effect.
The orvinol scaffold buries deep, hydrophobic contacts (the C7 tert-butyl/carbinol side chain) that give an exceptionally long receptor residence time. Buprenorphine dissociates from MOR with a half-life of tens of minutes to hours — driving its long duration and its resistance to naloxone reversal.
High affinity + slow off-rate means buprenorphine occupies and holds MOR against full agonists. It blunts the effect of subsequently taken heroin or fentanyl (a "blockade" or antagonist-like effect at the receptor level) — useful for maintenance, dangerous during induction.
Very high κ-opioid affinity (Ki ~0.07–0.8 nM) with negligible-to-low intrinsic activity — functionally a κ-antagonist. Blocking dysphoric, pro-stress KOR signalling is thought to contribute to its antidepressant/anti-anhedonic profile and low dysphoria.
δ-opioid affinity Ki ~1.2–6 nM, again with low efficacy — a δ-antagonist component. Contributes to the overall opioid receptor profile but is a minor player in the clinical effect.
Buprenorphine also engages the nociceptin/orphanin FQ receptor (NOP, ORL1) at Ki ~80–210 nM as a low-efficacy partial agonist. NOP activity modulates the analgesic ceiling and reward, and distinguishes buprenorphine from classical morphinans.
The clinical signature falls straight out of the pharmacology: a drug that self-limits its own most dangerous effect. Because the MOR activation curve plateaus, escalating the buprenorphine dose past ~16–32 mg (sublingual) yields little additional respiratory depression in an opioid-experienced person — the opposite of fentanyl, whose dose-response for apnoea is effectively linear until you stop breathing.
Swallowed buprenorphine is almost worthless: extensive first-pass glucuronidation and CYP metabolism leave an oral bioavailability near 10%. Every clinical formulation therefore bypasses the gut — sublingual films/tablets (F ≈ 30%), transdermal patches (Butrans), buccal films (Belbuca), and long-acting subcutaneous depots (Sublocade, Brixadi). Once absorbed it is ~96% protein-bound (α- and β-globulin), highly lipophilic (logP ~4.4), and cleared slowly: the sublingual terminal half-life runs 24–42 h, and depot formulations extend exposure to weeks.
Metabolism runs on two tracks. CYP3A4 (with a minor CYP2C8 contribution) N-dealkylates buprenorphine to norbuprenorphine — a full MOR agonist and a potent respiratory depressant in its own right, but one that crosses the blood–brain barrier poorly, so its CNS contribution in adults is limited. In parallel, UGT1A1/1A3/2B7 glucuronidate both parent and norbuprenorphine to inactive, renally/biliary-excreted conjugates. Because CYP3A4 is central, strong 3A4 inhibitors (ritonavir, ketoconazole, some azoles) raise exposure and inducers (rifampicin, carbamazepine) lower it.
Buprenorphine is a foundational medication for opioid use disorder (OUD) and a potent analgesic, and every one of its clinical quirks traces to the same three physical facts: partial efficacy, very high affinity, and a very slow off-rate. Read together they explain both why it is unusually safe and why it is unusually easy to get wrong.
Partial MOR agonism means the dose-response curve for brainstem (pre-Bötzinger) respiratory suppression flattens. In opioid-tolerant people, pushing buprenorphine higher adds analgesia and sedation only marginally and apnoea barely at all — the property that makes fatal overdose on buprenorphine alone rare. This ceiling is real but conditional: it protects against monotherapy overdose, not against synergy with other CNS depressants (see §05).
At maintenance doses (≥16 mg/day) buprenorphine occupies the large majority of brain MOR and, because it dissociates so slowly, it stays there. A full agonist taken on top finds few free receptors and is outcompeted at those it reaches — the subjective "you can't feel the heroin" blockade that stabilises recovery. The same high occupancy is what makes a buprenorphine overdose relatively naloxone-resistant: reversal may need larger, repeated, or infused naloxone.
Give buprenorphine while a full agonist still occupies MOR and its high affinity strips the full agonist off the receptor while only partially activating in its place — net receptor signalling drops abruptly and the patient is thrown into acute, sometimes severe, precipitated withdrawal within an hour. Standard induction therefore waits until the person is already in mild-to-moderate spontaneous withdrawal (e.g. COWS ≥ 8–12) before the first dose. Long-half-life agonists like methadone, and the huge fat-depot reservoirs of illicit fentanyl, make this timing harder — the driver behind "low-dose"/micro-induction protocols.
The dynorphin/KOR system drives dysphoria, stress reactivity and anhedonia. Buprenorphine's high-affinity, low-efficacy occupancy of KOR functionally blocks that signalling, which is why it produces less dysphoria than pure µ-agonists and why buprenorphine (and the buprenorphine/samidorphan combination ALKS-5461) has been investigated for treatment-resistant depression.
Suboxone, Zubsolv, Bunavail, Cassipa combine buprenorphine with naloxone in a 4:1 ratio. Naloxone is a µ-antagonist that is almost inactive sublingually (bioavailability only a few percent) but well-absorbed if the film is dissolved and injected. Taken as directed, the naloxone does essentially nothing and the buprenorphine does the work. Diverted and injected by someone dependent on full agonists, the naloxone hits first and helps precipitate withdrawal — an abuse-deterrent, not a rescue agent. It is not there to reverse a buprenorphine overdose.
Mono-product buprenorphine (Subutex, Sublocade depot) is preferred in pregnancy and where the naloxone component is unwanted. Naloxone-in-the-film is a clever exploitation of a route-dependent bioavailability gap — not a safety ceiling of its own.
Buprenorphine is a conformationally locked molecule. The oripavine core is a fused, bridged
pentacyclic cage; the 6,14-ethano bridge welds the C-ring rigid, and only the C7 side chain
(the tert-butyl carbinol) and the N-cyclopropylmethyl arm retain meaningful torsional freedom
(ChEMBL reports just 4 rotatable bonds). In FlexAID∆S terms this means a small conformational-entropy
penalty ΔS_conf on binding: the ligand is pre-organised, arriving at MOR already shaped
like its bound pose, so little entropy is spent freezing it.
The affinity story is therefore enthalpy-and-residence-driven. The deep, hydrophobic
burial of the C7 side chain into the MOR pocket (the same sub-pocket the orvinol BU72 exploits in PDB 5C1M)
maximises van der Waals contact and expels ordered water, and — because so few degrees of freedom must be
quenched — the bound complex sits in a narrow, low-entropy basin. Shannon entropy of the pocket
H_pocket, high and multi-modal in the apo receptor, collapses sharply as the rigid cage
docks and clamps the transmembrane bundle: a textbook entropy-collapse fingerprint of a
high-affinity, slow-dissociating ligand.
That same narrow basin is the physical origin of the clinically decisive slow koff:
escaping requires re-populating a high-entropy transition state the rigid ligand reaches only rarely, so
dissociation is slow and residence time long. A theoretical ΔG from the observed Ki ~0.2 nM is
ΔG = −RT·ln(1/Ki) ≈ −13.2 kcal/mol at 310 K — deep, and made durable by the
entropic reluctance to leave. Contrast fentanyl: higher intrinsic efficacy but a floppier scaffold and faster
off-rate. Buprenorphine trades maximal drive for a grip that neither the receptor nor a competing agonist can
easily break — the molecular reason it both blocks other opioids and resists naloxone.
Buprenorphine is one of the safest opioids to take alone and one of the most life-saving in OUD treatment. That safety is conditional, route-dependent, and easy to void. Non-moralistic, evidence-based.
| Target | Affinity | Rel. | Mechanism |
|---|---|---|---|
|
MOR
µ-opioid receptor (OPRM1)
|
Ki ≈ 0.2 nM
range 0.09–1.5 nM · primary
|
Partial agonist | |
|
KOR
κ-opioid receptor (OPRK1)
|
Ki ≈ 0.1 nM
range 0.04–0.8 nM
|
Antagonist | |
|
DOR
δ-opioid receptor (OPRD1)
|
Ki ≈ 1.5 nM
range 1.2–6.1 nM
|
Antagonist | |
|
NOP
Nociceptin receptor (OPRL1 / ORL1)
|
Ki ≈ 90 nM
range 77–212 nM
|
Partial agonist | |
|
Norbup.
Norbuprenorphine → MOR (metabolite)
|
Ki ≈ 0.1–0.2 nM
full agonist · poor CNS entry
|
Full agonist |